AcouSort receives Notice of Allowance in the US for patent on plastic chips

Regulatory

The US patent authorities, USPTO, have issued a Notice of Allowance for one of AcouSort’s patent applications. The patent covers how to design and drive acoustofluidic devices made in plastic. The invention was originally acquired from the Technical University of Denmark (DTU) in 2018.

In 2018 AcouSort acquired an invention from DTU that describes a new way of designing and operating acoustofluidic devices made of soft materials such as polymers, in order to be able to replace components made of silicon or glass.

Since the acquisition of the patent rights from DTU, AcouSort, Lund University, DTU and the Danish company Ortofon have jointly worked on developing practical designs and methods for producing polymer based devices through the AcouPlast project supported by Eurostars/Vinnova.

Together with another invention concerning a new and more efficient way of manufacturing AcouSort’s acoustic chip, which AcouSort acquired from DTU in 2021, separation modules will be easier to manufacture at high volumes in a more cost-effective way. It will take at least 3-4 years of further research and development before the new type of plastic chip acquires a commercial significance.

– The business potential of making separation modules in plastic instead of glass should not be underestimated, especially in combination with the second invention that we acquired from DTU, targeting how to produce ultrasound in a more inexpensive way. The road is now paved towards producing low-cost separation modules enabling the application of one-time-use consumables. Such consumables are most often required when handling blood samples from patients in primary care or therapeutic settings in order to avoid potential cross contamination between patient samples, says AcouSort’s CEO Torsten Freltoft.

This information is such information that Acousort AB (publ) is obliged to publish in accordance with the EU Market Abuse Regulation. The information was submitted, through the agency of the contact person below, for publication on February 18, 2022 at 13.05 CET.

For further information on AcouSort, please contact:

Torsten Freltoft, CEO
Telephone: +45 2045 0854
E-mail: torsten.freltoft@acousort.com

About AcouSort

AcouSort AB (corporate registration number 556824-1037) is an innovative technology company focusing on developing products and solutions for integrated preparation of biological samples. With the help of sound waves, the company’s products can separate blood cells, concentrate, purify and stain cells, exosomes and bacteria from biological samples. The technology of the company’s products is acoustofluidics, where sound waves and microfluidics enable automated handling of samples in a range of application areas, from research on new biomarkers to the development of new diagnostic systems for near-patient testing – so-called Point-of Care (POC) systems. The company’s commercialization strategy is based on the already proven business model of providing separation modules to diagnostic system manufacturers for integrated sample preparation as well as to continue the commercialization of the company’s research instruments. With the help of the company’s products and development of point-of-care tests, new diagnostic systems and treatments are enabled, addressing some of the most challenging disease areas of our time: cancer, infectious diseases and cardiovascular diseases. AcouSort is listed at Nasdaq First North Growth Market. The company’s Certified Adviser is Erik Penser Bank, 08-463 83 00, certfiedadviser@penser.se.Erik Penser Bank AB (publ), Apelbergsgatan 27, Box 7405, 103 91 Stockholm.